Satellos Bioscience Inc.
MSLE
NASDAQ8.27
USD
+0.85
- -
CIK
0001421642
ISIN
CA80401L8033
CUSIP
80401L803
Return %
Stock
S&P500
1Y
16.81
21.04
3Y
16.81
70.88
5Y
16.81
73.53
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Frank Gleeson
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Royal Bank Plaza Toronto ON Canada M5J 2J1
- IPO Date
- Aug 3, 2012
- CIK
- 0001421642
- Website
- satellos.com
- Similar Companies
- Business
- Satellos Bioscience Inc. is a biotechnology company specializing in regenerative medicine focused on degenerative muscle diseases, operating primarily in Canada with subsidiaries in Australia and the United States; it develops novel small-molecule therapeutics using its proprietary MyoReGenX platform to analyze muscle stem cell polarity and regeneration ex vivo and to identify actionable targets for therapy; the company’s lead program, SAT-3247, is an oral small-molecule candidate in clinical development intended to modify disease progression in Duchenne muscular dystrophy by promoting endogenous muscle repair pathways; Satellos leverages collaborations and licenses, including engagements with research institutes, to advance its pipeline toward first-in-human trials and beyond. Satellos was founded in 2018 and is headquartered in Toronto, Ontario. The company pursues a focused pipeline in rare muscular disorders and regenerative medicine, with ongoing development activities and strategic partnerships to support clinical advancement and potential future commercialisation. Recent major changes include advancement of SAT-3247 into clinical development, engagement with contract research and manufacturing organizations to support GLP toxicology studies and GMP manufacturing, and ongoing plans for Phase 1b/Phase 2 development, alongside operational expansions and continued strategic collaborations to broaden its research and development footprint. Satellos’ product and service offerings span discovery and preclinical research services, translational and clinical development of regenerative medicines, and related partnership arrangements to accelerate clinical progression and potential therapeutic availability. The company maintains a visible research emphasis in Canada while leveraging international collaborations to support its development programs, and it positions itself as a specialized player in the field of muscle regeneration with an emphasis on restoring the body’s innate repair mechanisms. The corporate profile reflects a clinical-stage, research-driven biotechnology enterprise dedicated to transformative therapies for Duchenne muscular dystrophy and related muscular dystrophies, underpinned by a focus on stem cell biology and regenerative pathways.
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos to Participate in Upcoming Investor Conferences
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More